Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Abbott Park, Illinois
- Most recent report
- 10-Q, filed Nov 4, 2026
- Incorporated
- Illinois
- Filings on record
- 1,001+ filings
- On EDGAR
- CIK 1800
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 34
News 8 of 89
Prospectuses and Registrations 8 of 16
- S-8 Registration statement for an employee plan Apr 24, 2026
- S-8 Registration statement for an employee plan Mar 23, 2026
- 424B5 Prospectus supplement for an offering Feb 25, 2026
- FWP Free writing prospectus Feb 24, 2026
- 424B3 Prospectus supplement for an offering Feb 23, 2026
- S-3ASR Automatic shelf registration Feb 23, 2026
- S-3ASR Automatic shelf registration May 3, 2023
- S-8 Registration statement for an employee plan Dec 14, 2020
Proxies 8 of 25
- DEFA14A Extra proxy material Mar 13, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 13, 2026
- DEFA14A Extra proxy material Mar 14, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 14, 2025
- DEFA14A Extra proxy material Mar 15, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 15, 2024
- PX14A6G Shareholder's own proxy material Apr 10, 2023
- PX14A6G Shareholder's own proxy material Apr 5, 2023
Ownership 8 of 811
- 4 Insider reported a trade Nov 6, 2026
- 144 Notice of a proposed sale of restricted stock Nov 5, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Sep 25, 2026
Other 8 of 26
- 11-K Employee stock plan report Jun 18, 2026
- SD Conflict minerals disclosure May 27, 2026
- ARS Annual report sent to shareholders Mar 13, 2026
- 11-K Employee stock plan report Jun 20, 2025
- SD Conflict minerals disclosure May 29, 2025
- ARS Annual report sent to shareholders Mar 14, 2025
- 11-K Employee stock plan report Jun 25, 2024
- SD Conflict minerals disclosure May 30, 2024
What to read: Sep 2026 10-Q
SECSift found 3 of 9 sections worth reading, with 0 positive, 9 notable, and 4 negative flags.
Balance Sheet
Massive NEC litigation charge, IRS SNODs, Exact Sciences acquisition, and Nutrition spin-off announced.Notable- IRS SNODs total $1.05B for 2017-2020 tax years, contesting income reallocation; Abbott filed Tax Court petitions.
- Exact Sciences acquisition added $321M stock comp expense in first nine months 2026 from cash settlement of equity awards.
- Abbott announced plan to spin off Nutrition business as independent public company by end of 2027 via tax-free distribution.
Negative- Recorded $670M charge in Q3 2026 to settle NEC lawsuits covering ~2,000 infants; no reserve for remaining cases.
- Paid $385M in September 2026 to resolve DOJ False Claims Act probe into infant formula manufacturing.
- Malaysian tax assessment of $413M for 2023 upheld by Penang High Court; Abbott appealed in October 2025.
Item 2
Major acquisition, nutrition spin-off, IRS disputes, and detailed segment results with numbers.Notable- Gross margin fell to 50.3% in Q3 2026 from 51.7%, due to higher intangible amortization from Exact Sciences.
- Interest expense surged $253M to $297M in Q3 2026 from debt issued for the $20.6B Exact Sciences acquisition.
- Abbott plans to spin off its Nutrition business into a publicly traded company by end of 2027.
- Operating cash flow fell ~$700M to $5.5B in 9 months 2026, due to legal settlements and higher inventory.
- Abbott repurchased 11.6M shares for $1.0B in 9 months 2026; $5.6B remains authorized under the program.
Legal Proceedings (Item 1)
Settlement of DOJ infant formula investigation for $385M, a material resolved liability.
What changed: Sep 2026 vs. Jun 2026
About 3% of ABT's Sep 2026 10-Q is new information. 10 paragraphs were added, 96 changed, and 14 removed. Below are the most important lines SECSift identified.
Changed
- Exact Sciences intangible assets rose to $16.0B from $12.8B; goodwill fell to $8.9B from $11.4B; deferred taxes rose to $(2.7)B from $(2.0)B.
- R&D expenses rose to $920M in Q3 2026 from $892M in Q2 2026; nine-month total rose to $2.6B from $1.7B.
- SG&A expenses rose to $4.3B in Q3 2026 from $4.0B in Q2 2026; nine-month total rose to $12.0B from $7.8B.
- Foreign currency hedging instruments asset fell to $139M from $152M at June 30, 2026.
- Foreign currency hedging instruments liability dropped to $94M from $109M at June 30, 2026.
- Interest rate swaps non-current liability rose to $267M from $100M at June 30, 2026.
- Net investment hedge debt rose to $584M from $568M at June 30, 2026.
- Remaining buyback authority stayed at $5.65 billion, unchanged from June 2026.
- Total fair value liabilities rose to $1,045M from $878M at June 30, 2026.
- Exhibit 101 period changed from six months ended June 30, 2026 to nine months ended September 30, 2026.
Removed
- Average price paid per share was $89.70 in prior period; no purchases in current period.
- NEC lawsuits and $495 million Gill verdict appeal no longer mentioned.
- Abbott bought no shares in July-September 2026, after buying 11.6 million shares in April-June 2026.
- Prior filing showed 3.5M, 3.6M, and 4.5M shares bought each month; current shows none.
- Shareholder derivative lawsuit settlement in June 2026 no longer mentioned.
Everything here comes from Abbott Laboratories's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 4, 2026, from the 10-Q for Sep 2026.